Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | GLI2 | P10070 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558403 | 1.00 | CYP51A1 (0.47) | CYP51A1ADRB3ADRB1ADRB2CYP17A1 | |
| SCHEMBL4584050 | 0.89 | ADRB3 (0.47) | CYP51A1ADRB3ADRB1ADRB2 | |
| SCHEMBL4584053 | 0.89 | ADRB3 (0.47) | CYP51A1ADRB3ADRB1ADRB2 | |
| SCHEMBL4479042 | 0.86 | GLI1 (0.50) | GLI1GLI2 | |
| SCHEMBL4479037 | 0.86 | GLI1 (0.50) | GLI1GLI2 | |
| SCHEMBL4584190 | 0.84 | ADRB3 (0.46) | CYP51A1ADRB3ADRB1ADRB2 | |
| SCHEMBL4584186 | 0.84 | ADRB3 (0.46) | CYP51A1ADRB3ADRB1ADRB2 | |
| SCHEMBL4464277 | 0.81 | GLI1 (0.38) | CYP51A1ADRB3ADRB1GLI1GLI2 | |
| SCHEMBL4464282 | 0.81 | GLI1 (0.38) | CYP51A1ADRB3ADRB1GLI1GLI2 | |
| SCHEMBL4478536 | 0.80 | FFAR1 (0.38) | CYP51A1ADRB3ADRB1GLI1GLI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | CYP51A1 1727/4885ADRB3 130/4885ADRB1 39/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | CYP51A1 1390/4885ADRB3 568/4885ADRB1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.